A majority of the Fortune 500 Companies implement some practice of workplace drug testing in their company policies. This practice was first initiated by President Ronald Reagan when he ordered federal agencies to drug test federal employees involved in sensitive positions as well as positions involving public safety. As a practicing toxicologist, Dr. Amitava Dasgupta is involved with the pre-employment drug testing at his own hospital and aptly shares his expertise in Beating Drug Tests and Defending Positive Results: A Toxicologist’s Perspective, which covers all major issues concerning how people try to beat drug tests and defend positive test results. In each chapter, extensive references are cited so that readers can access more information on a particular topic that may interest them. The book will undoubtedly prove helpful to toxicologists, medical technologists, pathologists, human resources professionals and anyone interested in workplace drug testing.

A majority of the Fortune 500 Companies implement some practice of workplace drug testing in their company policies. This practice was first initiated by President Ronald Reagan when he ordered federal agencies to drug test federal employees involved in sensitive positions as well as positions involving public safety. As a practicing toxicologist, Dr. Amitava Dasgupta is involved with the pre-employment drug testing at his own hospital and aptly shares his expertise in Beating Drug Tests and Defending Positive Results: A Toxicologist's Perspective, which covers all major issues concerning how people try to beat drug tests and defend positive test results. In each chapter, extensive references are cited so that readers can access more information on a particular topic that may interest them. The book will undoubtedly prove helpful to toxicologists, medical technologists, pathologists, human resources professionals and anyone interested in workplace drug testing.

Critical Issues in Alcohol and Drugs of Abuse Testing, Second Edition, addresses the general principles and technological advances for measuring drugs and alcohol, along with the pitfalls of drugs of abuse testing. Many designer drugs, for example, are not routinely tested in drugs of abuse panels and may go undetected in a drug test. This updated edition is a must-have for clinical pathologists, toxicologists, clinicians, and medical review officers and regulators, bridging the gap between technical and clinical information. Topics of note include the monitoring of pain management drugs, bath salts, spices (synthetic marijuana), designer drugs and date rape drugs, and more. - Serves as a ready resource of information for alcohol and drug testing - Ideal resource for making decisions related to the monitoring and interpretation of results - Includes concise content for clinical laboratory scientists, toxicologists and clinicians

This comprehensive text provides clear explanations of the effects of drugs on human performance and the need for workplace drug testing. It provides essential information on the regulatory and legal frameworks around the world, how to set policies and coverage of all aspects of drug analysis and the associated interpretation of results.Contents include:* epidemiology of drug use in the working population* the evidence base and guidelines for workplace drug testing* legal, regulatory aspects and policies for drugs and alcohol* urine and alternative sample collection process* analytical techniques and specimen adulteration.Case studies of successful programmes are also included to illustrate the principles discussed.Written by internationally acknowledged experts this informative book will be essential reading for anyone interested in workplace drug testing or setting up such a system including clinical and forensic toxicologists, occupational health physicians, nurses, human resources, drug counselling and treatment providers, analytical chemists and lawyers.Alain Verstraete is Professor at the Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium and Department Head of the Toxicology Laboratory of the Laboratory of Clinical Biology, Ghent University Hospital, Ghent, Belgium.

"The growing pressures in society and government for drug testing programs and the intrusiveness of both testing procedures and their results on personal privacy led the Privacy Commissioner to undertake a review of federal government drug testing policy and practice. While there is no doubt that drug testing infringes personal privacy in a profound sense, one must not be blind to the need to protect the public interest. R.I.D.E. programs, for example, are seen as justifiable intrusions on private rights to safeguard the public good, even in light of the Charter of Rights. The recommendations contained in this report are offered as a contribution to the ongoing debate and a guide to government. The development of drug testing policies and practices which respect the requirements of the Privacy Act and which keep in appropriate balance public and private rights will be a unique anddifficult challenge"--Introduction, p.2.